Royalty Pharma Deal History & Licensing Activity
Royalty Pharma is a large biotech headquartered in USA. Over the past three years, Royalty Pharma has been involved in 4 licensing and acquisition transactions, with a primary focus on Antibodies (4 deals).
Deals (12mo)
2
Active Trials
0
Top Modality
Antibodies
Focus Area
Mega Deals
Royalty Pharma Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Royalty Pharma in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| daraxonrasib | Revolution Medicines | Small Molecules | Phase 3 | license | Jul 10, 2026 |
| TEV-53408 | Teva Pharmaceuticals | Antibodies | Phase 2 | license | Jan 15, 2026 |
Royalty Pharma Pipeline Focus
Therapeutic areas and modalities where Royalty Pharma is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Royalty Pharma Strategic Signals
Key indicators of Royalty Pharma's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
See How Your Asset Matches Royalty Pharma's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Mega Deals assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Dermatology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for dermatology
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
About Royalty Pharma Licensing & Deal Activity
Royalty Pharma is a large biotech company based in USA that has been actively engaged in licensing transactions across the biopharma landscape. With 4 deals over the past three years, Royalty Pharma ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Royalty Pharma include Mega Deals (2 deals and trials), Dermatology (2 deals and trials), and Immunology (2 deals and trials). In terms of modality, Royalty Pharma has shown particular interest in antibodies, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Royalty Pharma and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Royalty Pharma's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.